术前无创方式预测胰腺神经内分泌肿瘤分级的研究现状及进展
Research Status and Progress of Preoperative Noninvasive Prediction of Pan-creatic Neuroendocrine Tumor Grade
DOI: 10.12677/ACM.2023.133533, PDF,   
作者: 钟 涛, 李金政*：重庆医科大学第二附属医院肝胆外科，重庆
关键词: 胰腺神经内分泌肿瘤；术前预测；肿瘤分级；Pancreatic Neuroendocrine Tumor； Preoperative Prediction； Tumor Grade
摘要: 胰腺神经内分泌肿瘤是起源于胰腺内分泌细胞的一种异质性肿瘤，其肿瘤分级与疾病预后密切相关，G2和G3级的肿瘤预后较差，比G1肿瘤需要更积极的手术治疗。因此，术前明确肿瘤的分级对患者的后期治疗策略的制定及预后的评估具有极其重要的指导作用，本文就术前无创方式预测胰腺神经内分泌肿瘤分级的研究进展进行了综述。
Abstract: Pancreatic neuroendocrine tumor is a heterogeneous tumor originating from pancreatic endocrine cells. Its tumor grade is closely related to the prognosis of the disease. The prognosis of G2 and G3 tumors is poor, and more aggressive surgical treatment is needed than G1 tumors. Therefore, pre-operative determination of tumor grading plays an extremely important role in guiding the formu-lation of late treatment strategies and the evaluation of prognosis of patients. This article reviews the research progress of preoperative non-invasive prediction of pancreatic neuroendocrine tumor grading.
文章引用：钟涛, 李金政. 术前无创方式预测胰腺神经内分泌肿瘤分级的研究现状及进展[J]. 临床医学进展, 2023, 13(3): 3716-3722. https://doi.org/10.12677/ACM.2023.133533

参考文献

[1] Lawrence, B., Gustafsson, B.I., Chan, A., et al. (2011) The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology & Metabolism Clinics of North America, 40, 1-18. [Google Scholar] [CrossRef] [PubMed]
[2] Bettini, R., Partelli, S., Boninsegna, L., et al. (2011) Tumor Size Correlates with Malignancy in Nonfunctioning Pancreatic Endocrine Tumor. Surgery, 150, 75-82. [Google Scholar] [CrossRef] [PubMed]
[3] 吴文铭, 陈洁, 白春梅, 依荷芭丽•迟, 杜奕奇, 冯仕庭, 霍力, 姜玉新, 李景南, 楼文晖, 罗杰, 邵成浩, 沈琳, 王峰, 王理伟, 王鸥, 王于, 吴焕文, 邢小平, 徐建明, 薛华丹, 薛玲, 杨扬, 虞先濬, 原春辉赵宏, 朱雄增, 赵玉沛. 中国胰腺神经内分泌肿瘤诊疗指南(2020) [J]. 协和医学杂志, 2021, 12(4): 460-480.
[4] Panzuto, F., Boninsegna, L., Fazio, N., et al. (2011) Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated with Disease Progression. Journal of Clinical Oncol-ogy, 29, 2372-2377. [Google Scholar] [CrossRef] 
[5] Han, X., Zhang, C., Tang, M., et al. (2015) The Value of Serum Chromogranin A as a Predictor of Tumor Burden, Therapeutic Response, and Nomogram-Based Survival in Well-Moderate Nonfunctional Pancreatic Neuroendocrine Tumors with Liver Metastases. European Journal of Gastro-enterology & Hepatology, 27, 527-535. [Google Scholar] [CrossRef] 
[6] Pulvirenti, A., Rao, D., Mcintyre, C.A., et al. (2019) Lim-ited Role of Chromogranin A as Clinical Biomarker for Pancreatic Neuroendocrine Tumors. HPB (Oxford), 21, 612-618. [Google Scholar] [CrossRef] [PubMed]
[7] 夏艳艳, 沈瀚, 许红攀, 李智洋. 液体活检技术在肿瘤诊断中的最新研究进展[J]. 现代检验医学杂志, 2021, 36(3): 157-160.
[8] 邢加彰, 程月鹃, 白春梅. NETest液体活检技术在神经内分泌瘤诊疗领域研究进展[J]. 中国肿瘤, 2021, 30(10): 789-793.
[9] Modlin, I.M., Kidd, M., Falconi, M., et al. (2021) A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease Outperforms CgA and Has Surgical and Clinical Utility. Annals of Oncology, 32, 1425-1433. [Google Scholar] [CrossRef] [PubMed]
[10] Öberg, K., Califano, A., Strosberg, J.R., et al. (2020) A Me-ta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood. Annals of On-cology, 31, 202-212. [Google Scholar] [CrossRef] [PubMed]
[11] Lambin, P., Rios-Velazquez, E., Leijenaar, R., et al. (2012) Ra-diomics: Extracting More Information from Medical Images Using Advanced Feature Analysis. European Journal of Cancer, 48, 441-446. [Google Scholar] [CrossRef] [PubMed]
[12] Litvin, A.A., Burkin, D.A., Kropinov, A.A. and Paramzin, F.N. (2021) Radiomics and Digital Image Texture Analysis in Oncology (Review). Sovremennye Tehnologii v Medicine, 13, 97-104. [Google Scholar] [CrossRef] [PubMed]
[13] 覃山羽. 超声内镜在胰腺神经内分泌肿瘤诊治中的新进展[J]. 中华消化内镜杂志, 2022, 39(8): 611-615.
[14] Khashab, M.A., Yong, E., Lennon, A.M., et al. (2011) EUS Is Still Superior to Multidetector Computerized Tomography for Detection of Pancreatic Neuroendocrine Tumors. Gas-trointestinal Endoscopy, 73, 691-696. [Google Scholar] [CrossRef] [PubMed]
[15] Puli, S.R., Kalva, N., Bechtold, M.L., et al. (2013) Diagnostic Ac-curacy of Endoscopic Ultrasound in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. World Journal of Gastroenterology, 19, 3678-3684. [Google Scholar] [CrossRef] [PubMed]
[16] Palazzo, M., Napoléon, B., Gincul, R., et al. (2018) Contrast Har-monic EUS for the Prediction of Pancreatic Neuroendocrine Tumor Aggressiveness (with Videos). Gastrointestinal En-doscopy, 87, 1481-1488. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, K., Zhang, W., Zhang, Z., et al. (2018) Simple Vascular Ar-chitecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis. Digestive Diseases and Sciences, 63, 3147-3152. [Google Scholar] [CrossRef] [PubMed]
[18] 杨甜甜. 胰腺神经内分泌肿瘤的CT表现与病理分级的相关性研究[D]: [硕士学位论文]. 济南: 济南大学, 2017.
[19] 韩滨泽, 纪元, 曾蒙苏, 王明亮. 胰腺神经内分泌肿瘤计算机断层扫描增强特征对术前病理分级的预测价值[J]. 中华消化杂志, 2021, 41(9): 613-618.
[20] Canellas, R., Burk, K.S., Parakh, A. and Sahani, D.V. (2018) Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. AJR American Journal of Roentgenology, 210, 341-346. [Google Scholar] [CrossRef] 
[21] 代博, 王梅云, 闫峰山, 贺慧, 窦社伟, 张孝先, 谭红娜. MRI在G1/G2胰腺神经内分泌肿瘤病理分级及临床分期中的价值[J]. 放射学实践, 2022, 37(1): 72-78. [Google Scholar] [CrossRef] 
[22] Jang, K.M., Kim, S.H., Lee, S.J. and Choi, D. (2014) The Value of Gadoxetic Acid-Enhanced and Diffusion-Weighted MRI for Prediction of Grading of Pancreatic Neuroen-docrine Tumors. Acta Radiologica, 55, 140-148. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, C., Bian, Y., Meng, Y., et al. (2022) Preoperative Prediction of G1 and G2/3 Grades in Patients with Nonfunctional Pancreatic Neuroendocrine Tumors Using Multimodality Imaging. Academic Radiology, 29, e49-e60. [Google Scholar] [CrossRef] [PubMed]
[24] Bian, Y., Li, J., Cao, K., et al. (2021) Magnetic Resonance Imaging Radiomic Analysis Can Preoperatively Predict G1 and G2/3 Grades in Patients with NF-pNETs. Abdominal Radiology (NY), 46, 667-680. [Google Scholar] [CrossRef] [PubMed]
[25] Treglia, G., Castaldi, P., Rindi, G., Giordano, A. and Rufini, V. (2012) Diagnostic Performance of Gallium-68 Somatostatin Receptor PET and PET/CT in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumours: A Meta-Analysis. Endocrine, 42, 80-87. [Google Scholar] [CrossRef] [PubMed]
[26] Niederle, B., Pape, U.F., Costa, F., et al. (2016) Vienna Consen-sus Conference Participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology, 103, 125-138. [Google Scholar] [CrossRef] [PubMed]
[27] Rinzivillo, M., Partelli, S., Prosperi, D., et al. (2018) Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. Oncologist, 23, 186-192. [Google Scholar] [CrossRef] [PubMed]
[28] Mapelli, P., Partelli, S., Salgarello, M., et al. (2020) Dual Tracer 68Ga-DOTATOC and 18F-FDG PET/Computed Tomography Radiomics in Pancreatic Neuroendocrine Neo-plasms: An Endearing Tool for Preoperative Risk Assessment. Nuclear Medicine Communications, 41, 896-905. [Google Scholar] [CrossRef] 
[29] Zhou, J., Zhao, R., Pan, Y., et al. (2022) The Diagnostic and Grading Accuracy of 68Ga-DOTATATE and 18F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms. Fron-tiers in Oncology, 12, Article ID: 796391. [Google Scholar] [CrossRef] [PubMed]

为你推荐